Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 7, 2016, Pages 1333-1337

  Anderlini, Paolo ^a   Saliba, Rima M ^a   Ledesma, Celina ^a   Plair, Tamera ^a   Alousi, Amin M ^a   Hosing, Chitra M ^a   Khouri, Issa F ^a   Nieto, Yago ^a   Popat, Uday R ^a   Shpall, Elizabeth J ^a   Fanale, Michelle A ^a   Hagemeister, Frederick B ^a   Oki, Yasuhiro ^a   Neelapu, Saatva ^a   Romaguera, Jorge E ^a   Younes, Anas ^b   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Allogeneic stem cell transplantation; Bone marrow transplantation; Brentuximab vedotin; Hodgkin lymphoma

Indexed keywords

BRENTUXIMAB VEDOTIN; FLUDARABINE; GEMCITABINE; MELPHALAN; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY; ANTIBODY CONJUGATE; DEOXYCYTIDINE; VIDARABINE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CLINICAL ARTICLE; DRUG DOSE INTENSIFICATION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; LUNG EDEMA; LUNG TOXICITY; MALE; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RASH; REDUCED INTENSITY CONDITIONING; RESPIRATORY DISTRESS; SKIN TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPLICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LUNG DISEASE; MIDDLE AGED; MORTALITY; PROCEDURES; REMISSION; SALVAGE THERAPY; SKIN DISEASE; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

ADULT; DEOXYCYTIDINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; LUNG DISEASES; MALE; MELPHALAN; MIDDLE AGED; NAUSEA; REMISSION INDUCTION; SALVAGE THERAPY; SKIN DISEASES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; YOUNG ADULT;

EID: 84969222363     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2016.03.028     Document Type: Article

References (17)

1. Kharfan-Dabaja M.A., Hamadani M., Sibal H., Savani B.N. Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!. Bone Marrow Transplant 2014, 49:599-606.
2. Robinson S.P., Sureda A., Canals C., et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009, 94:230-238.
3. Ansell S.M. Brentuximab vedotin. Blood 2012, 120:560-568.
4. Oki Y., Younes A. Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk Lymph 2008, 49:883-889.
5. Aapro M.S., Martin C., Hatty S. Gemcitabine-a safety review. Anticancer Drugs 1998, 9:191-201.
6. Friedberg J.W., Neuberg D., Kim H., et al. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer 2003, 98:978-982.
7. Chen Y.M., Liu J.M., Tsai C.M., et al. Maculopapular rashes secondary to gemcitabine injection for non-small-cell lung cancer. J Clin Oncol 1996, 14:1743-1744.
8. Shanks R.H., Rizzieri D.A., Flowers J.L., et al. Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. Clin Cancer Res 2005, 11:4225-4233.
9. Anderlini P., Saliba R., Acholonu S., et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008, 93:257-264.
10. Anderlini P., Saliba R., Ledesma C., et al. Reduced-intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory Hodgkin lymphoma (HL) in the brentuximab vedotin era: favorable overall and progression-free survival (OS/PFS) with low transplant-related mortality (TRM). Blood 2013, 122:abstr 410.
11. NCI Common Terminology Criteria for Adverse Events. Available at: Accessed January 12, 2016. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
12. de Lima M., Anagnostopoulos A., Munsell M., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:865-872.
13. Gopal A.K., Chen R., Smith S.E., et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015, 125:1236-1243.
14. Bartlett N.L., Chen R., Fanale M.A., et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 2014, 7:24.
15. Ansell S.M. Targeting immune checkpoints in lymphoma. Curr Opin Hematol 2015, 22:337-342.
16. Chen R., Palmer J.M., Thomas S.H., et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012, 119:6379-6381.
17. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.